asston pharmaceuticals limited IPO
IPO Overview
Asston pharmaceuticals limited IPO is a SME public issue offered through a Book Building issue with a total issue size of ₹— crores. The IPO price band is set at ₹123 per share, and retail investors can apply with a minimum investment of ₹2.46 L as per IPO guidelines.
The Asston pharmaceuticals limited IPO opens on 9 Jul 2025 and closes on 11 Jul 2025. The IPO allotment is expected to be finalized on 14 Jul 2025, and the equity shares are proposed to be listed on BSE on 16 Jul 2025.
Investors can refer to the Asston pharmaceuticals limited IPO RHP-DRHP for detailed information. The issue is managed by Sobhagya Capital Options Ltd as the book running lead manager, while Maashitla Securities Private Limited is the registrar to the IPO. Before investing, market participants often review IPO details, valuation, PE ratio, financials, and risk factors.
About Company
The company offers a diverse range of products, including tablets, capsules, sachets, and syrups. Its product portfolio encompasses various therapeutic categories, such as analgesics, antibiotics, antifungals, vitamins, and more.
The company manufactures pharmaceutical products for direct sales and also on a contract manufacturing or loan license basis, primarily working on a principle-to-principle approach with various marketers.
The company is FDA certified by both Central and State FDA, accredited by NQA (Nuclear Quality Assurance), and complies with Quality Management System (QMS) standards, ensuring high-quality manufacturing.
Products:
Albendazole USP 400 mg: Albendazole USP 400 mg refers to a higher dosage of Albendazole, a broad-spectrum anthelmintic (anti-worm) medication that is used to treat various parasitic worm infections.
Diclofenac 100 mg: Diclofenac 100 mg refers to a specific dosage of Diclofenac, a widely used nonsteroidal anti-inflammatory drug (NSAID).
Ibuprofen, paracetamol: Ibuprofen and Paracetamol (Acetaminophen) are two commonly used over-the-counter medications, often used to relieve pain and reduce fever.
Ferrovit Syrup: To treat vitamin and mineral deficiencies.
As of 3 July 2025, the company has 46 Permanent employees and 6 contractual employees in various departments.
Competitive Strengths:
Formulation Expertise
Experienced Promoters
Wide range of Products
Strategic Location
Skilled Workforce
Investment Objective
Funding the incremental working capital requirements of the Company
Repayment and/or prepayment, in part or full, of certain of the outstanding borrowings availed by the Company
General Corporate Purposes